Combining Camrelizumab with chemotherapy for left-sided obstructive colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of Camrelizumab, an anti-PD-1 immunotherapy, in combination with neoadjuvant chemotherapy for patients with left-sided obstructive colorectal cancer who have undergone stent placement. The approach aims to improve overall survival by addressing micrometastasis and enhancing the success rate of primary anastomosis while reducing the risk of stoma formation. Patients will receive treatment after stenting, allowing for better bowel decompression before surgery. The study evaluates the effectiveness of this combined treatment in improving patient outcomes compared to traditional emergency surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma
* Able to give written, informed consent
* Primary tumor was resectable
* ECOG score 0 or 1
* Haemoglobin greater than 100 g/L after transfusion before chemotherapy,
* White blood cells greater than 3.0×10# /L
* Platelets greater than 100×10# / L;
* Glomerular filtration rate greater than 50 mL per minute as calculated by the Wright or Cockroft formula
* Bilirubin less than 1.5×Upper Limit of Normal(ULN)
* ALT and AST less than 2.5×ULN

Exclusion Criteria:

* Distal rectal cancers(equal or less than 10cm from the anal verge)
* Patients with signs of peritonitis and/or bowel perforation
* Patients who did not give informed consent
* Patients who were considered unfit for operative treatment or refuse surgery.
* Patients with suspected or proven metastatic adenocarcinoma;
* Patients with unresectable colorectal cancer, or planning for palliative treatment.

Where it's running

• Beijing Chaoyang Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Zhen Jun Wang, MD — Beijing Chao Yang Hospital
• Study coordinator: Jia Gang Han, MD
• Email: hjg211@163.com
• Phone: +861085231604

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Combining camrelizumab with chemotherapy for lung cancer treatment

  This study is testing if combining a new drug called camrelizumab with chemotherapy can help people with certain types of lung cancer before surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06241807

• Combining chemotherapy with camrelizumab for non-small cell lung cancer patients after surgery

  This study is testing if combining chemotherapy with the immunotherapy drug camrelizumab helps patients with stage IIA-IIIA non-small cell lung cancer feel better after their surgery.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guandong, Guangdong · NCT05825443

• Combining camrelizumab and apatinib with TACE for liver cancer treatment

  This study is testing if combining two medications with a liver cancer treatment before surgery can help people with liver cancer live longer and have fewer problems after surgery.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05613478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.